Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
Price : $35 *
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary) ; Pazopanib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SOAP
- 21 Nov 2017 Status changed from recruiting to discontinued.
- 25 Aug 2017 Planned End Date changed from 1 May 2016 to 1 May 2018.
- 25 Aug 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2017.